Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027885 · ClinicalTrials.gov registry record · Phase 2
Phase II Bevacizumab + Tax In Advanced Breast Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00027885 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 49 participants.
The verdict
NCT00027885, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This randomized phase II trial is to see if docetaxel with or without bevacizumab followed by surgery, radiation therapy, and combination chemotherapy works better in treating patients who have stage III or stage IV breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- BIOLOGICAL bevacizumab
- PROCEDURE adjuvant therapy
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2001-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027885
The ClinicalTrials.gov registry entry for NCT00027885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00027885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027885 about?
NCT00027885 is a clinical study titled "Phase II Bevacizumab + Tax In Advanced Breast Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and h...
What is the current status of trial NCT00027885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2001-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00027885?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), bevacizumab (BIOLOGICAL), adjuvant therapy (PROCEDURE), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00027885?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.